Curcumin Cancer Research Results

CUR, Curcumin: Click to Expand ⟱
Features:
Curcumin is the main active ingredient in Tumeric. Member of the ginger family.Curcumin is a polyphenol extracted from turmeric with anti-inflammatory and antioxidant properties.
- Has iron-chelating, iron-chelating properties. Ferritin. But still known to increase Iron in Cancer cells.
- GSH depletion in cancer cells, exhaustion of the antioxidant defense system. But still raises GSH↑ in normal cells.
- Higher concentrations (5-10 μM) of curcumin induce autophagy and ROS production
- Inhibition of TrxR, shifting the enzyme from an antioxidant to a prooxidant
- Strong inhibitor of Glo-I, , causes depletion of cellular ATP and GSH
- Curcumin has been found to act as an activator of Nrf2, (maybe bad in cancer cells?), hence could be combined with Nrf2 knockdown
-may suppress CSC: suppresses self-renewal and pathways (Wnt/Notch/Hedgehog).
Clinical studies testing curcumin in cancer patients have used a range of dosages, often between 500 mg and 8 g per day; however, many studies note that doses on the lower end may not achieve sufficient plasma concentrations for a therapeutic anticancer effect in humans.
• Formulations designed to improve curcumin absorption (like curcumin combined with piperine, nanoparticle formulations, or liposomal curcumin) are often employed in clinical trials to enhance its bioavailability.

-Note half-life 6 hrs.
BioAv is poor, use piperine or other enhancers
Pathways:
- induce ROS production at high concentration. Lowers ROS at lower concentrations
curcumin can act as a pro-oxidant when blue light is applied
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells: GSH↓ Catalase↓ HO1↓ GPx↓
but conversely is known as a NRF2↑ activator in cancer
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, uPA↓, VEGF↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, GLi1↓, CD133↓, CD24↓, β-catenin↓, n-myc↓, sox2↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK↓, ERK↓, JNK, TrxR**,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Driver Suppression of survival and inflammatory transcription NF-κB is a primary, repeatedly validated curcumin target explaining pleiotropic downstream effects
2 STAT3 signaling ↓ STAT3 phosphorylation / activity ↔ or mild suppression Driver Loss of pro-survival and proliferative signaling STAT3 inhibition contributes to growth arrest, apoptosis sensitization, and reduced cytokine signaling in tumors
3 Reactive oxygen species (ROS) ↑ ROS (dose- & context-dependent) ↓ ROS / buffered Conditional Driver Biphasic redox modulation Curcumin can act as a pro-oxidant in cancer cells with high basal stress while acting antioxidant in normal cells
4 Mitochondrial integrity / intrinsic apoptosis ↓ ΔΨm; ↑ caspase activation ↔ preserved Driver Execution of intrinsic apoptosis Mitochondrial dysfunction and caspase activation occur downstream of NF-κB/STAT3 and ROS effects
5 PI3K → AKT → mTOR axis ↓ AKT / ↓ mTOR ↔ or adaptive suppression Secondary Reduced growth and anabolic signaling AKT/mTOR inhibition contributes to growth suppression and autophagy induction in cancer cells
6 Autophagy ↑ autophagy (protective or pro-death) ↑ adaptive autophagy Secondary Stress adaptation vs cell death Autophagy may be cytoprotective or cooperate with apoptosis depending on context and dose
7 HIF-1α / VEGF hypoxia–angiogenesis axis ↓ HIF-1α; ↓ VEGF ↔ minimal effect Secondary Anti-angiogenic pressure Suppression of hypoxia-driven transcription limits angiogenesis and tumor adaptation
8 Cell cycle regulation ↑ G2/M or G1 arrest ↔ largely spared Phenotypic Cytostatic growth control Cell-cycle arrest reflects upstream signaling and epigenetic effects rather than direct CDK inhibition
9 Migration / invasion (EMT, MMP axis) ↓ migration & invasion ↔ Phenotypic Anti-metastatic phenotype Reduced EMT markers and protease activity limit invasive behavior
10 Epigenetic regulation (p300/CBP HAT activity) ↓ histone acetylation ↔ modest Secondary Transcriptional reprogramming Curcumin modulates chromatin via HAT inhibition rather than classic HDAC inhibition


Scientific Papers found: Click to Expand⟱
1418- CUR,    Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis
- Review, Arthritis, NA
*COX2↓, *Inflam↓, *5LO↓, *NO↓, *NF-kB↓, *TNF-α↓, *IL1↓, *IL2↑, *IL6↓, *IL8↓, *IL12↓, *MCP1↓, *PGE2↓, *MMP2↓, *MMP3↓, *MMP9↓, *NLRP3↓, *ROS↓,
1485- CUR,  Chemo,  Rad,    Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs
- Review, Var, NA
ChemoSen↑, NF-kB↓, *STAT3↓, *COX2↓, *Akt↓, *NRF2↑, *HO-1↑, *GPx↑, *NADPH↑, *GSH↑, *ROS↓, *p300↓, radioP↑, chemoP↑, RadioS↑,
1486- CUR,    Curcumin and lung cancer--a review
- Review, Lung, NA
RadioS↑, ChemoSen↑,
1487- CUR,    Relationship and interactions of curcumin with radiation therapy
- Review, Var, NA
RadioS↑, ChemoSen↑,
1488- CUR,    Anti-Cancer and Radio-Sensitizing Effects of Curcumin in Nasopharyngeal Carcinoma
RadioS↑, ChemoSen↑,
1505- CUR,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
TumCCA↑, Apoptosis↑, DNMTs↓, HDAC↓, HATs↓, TumCP↓, p300↓, HDAC1↓, HDAC3↓, HDAC8↓, NF-kB↓,
1510- CUR,  Chemo,    Combination therapy in combating cancer
- Review, NA, NA
*NRF2↑, *GSH↑, *ROS↓, ChemoSideEff↓, eff↑, OS↓, chemoP↑,
1408- CUR,    Antiproliferative and ROS Regulation Activity of Photoluminescent Curcumin-Derived Nanodots
- in-vitro, Lung, A549
ROS↓, ROS↑,
1616- CUR,  EA,    Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid
- in-vitro, Nor, NA
*MAOA↓, *Dose∅, Dose?,
1792- CUR,  LEC,    Chondroprotective effect of curcumin and lecithin complex in human chondrocytes stimulated by IL-1β via an anti-inflammatory mechanism
- in-vitro, Arthritis, RAW264.7 - NA, NA, HCC-38
*Inflam↓, *NF-kB↓, *iNOS↓, *COX2↓, *NO↓, *PGE2↓, *MMPs↑, *TIMP1↑, *BioEnh↑,
1809- CUR,  Oxy,    Long-term stabilisation of myeloma with curcumin
- Case Report, Melanoma, NA
*OS↑, QoL↑, Dose↑, Dose↑, IL6↓, STAT3↓, NF-kB↓, COX2↓,
1977- CUR,    Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors
- in-vitro, BC, MCF-7 - in-vitro, Cerv, HeLa - in-vitro, Lung, A549
TrxR↓, Dose↝, eff↑,
1978- CUR,    Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells
- in-vitro, Cerv, HeLa
TrxR1↓, ROS↑, DNA-PK↑, eff↑, Trx↓, Trx1↓,
1979- CUR,  Rad,    Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase
- in-vitro, Lung, A549
eff↑, ROS↑, GSH/GSSG↓, TrxR↓, selectivity↑,
1980- CUR,  Rad,    Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells
- in-vitro, Cerv, HeLa - in-vitro, Laryn, FaDu
selectivity↑, RadioS↑, TrxR↓, ROS↑, ERK↑, Dose∅, cl‑PARP↑,
1981- CUR,    Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity
- in-vitro, Lung, NA
eff↑, ROS↑, mt-GSH↓, Bax:Bcl2↑, Cyt‑c↑, MMP↓, Casp3↑, Trx2↓, TrxR↓, mt-DNAdam↑,
1982- CUR,    Inhibition of thioredoxin reductase by curcumin analogs
- in-vitro, NA, NA
eff↑, TrxR↓,
483- CUR,  PDT,    Visible light and/or UVA offer a strong amplification of the anti-tumor effect of curcumin
- in-vivo, NA, A431
TumVol↓, TumCP↓, Apoptosis↑,
474- CUR,    Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2
TumCD↑, Apoptosis↑, DNAdam↑, γH2AX↑, TumCCA↑,
475- CUR,    Curcumin induces apoptotic cell death in human pancreatic cancer cells via the miR-340/XIAP signaling pathway
- in-vitro, PC, PANC1
Apoptosis↑, cl‑Casp3↑, miR-340↑, cl‑PARP↑, XIAP↓,
476- CUR,    The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer
- in-vitro, PC, PATU-8988 - in-vitro, PC, PANC1
TumCMig↓, TumCI↓, Apoptosis↑, NEDD9↓, p‑Akt↓, p‑mTOR↓, PTEN↑, p73↑, β-TRCP↑,
477- CUR,    Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells
- in-vitro, Cerv, SiHa
TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, CycB/CCNB1↓, CDC25↓, ROS↑, p62↑, LC3‑Ⅱ/LC3‑Ⅰ↑, cl‑Casp3↑, cl‑PARP↑, P53↑, P21↑,
478- CUR,    Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells
- in-vitro, Cerv, SiHa
EMT↓, N-cadherin↓, Vim↓, Slug↓, Zeb1↓, PIR↓, Pirin↓, E-cadherin↑,
479- CUR,    Curcumin Has Anti-Proliferative and Pro-Apoptotic Effects on Tongue Cancer in vitro: A Study with Bioinformatics Analysis and in vitro Experiments
- in-vitro, Tong, CAL27
TumCP↓, TumCMig↓, Apoptosis↑, TumCCA↑, Bcl-2↓, BAX↑, cl‑Casp3↑,
480- CUR,    Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells
- in-vitro, GBM, SNB19
TumCP↓, TumCMig↓, Apoptosis↑, TumCCA↑, NEDD9↓, NOTCH1↓, p‑Akt↓,
481- CUR,  CHr,  Api,    Flavonoid-induced glutathione depletion: Potential implications for cancer treatment
- in-vitro, Liver, A549 - in-vitro, Pca, PC3 - in-vitro, AML, HL-60
GSH↓, mtDam↑, MMP↓, Cyt‑c↑,
482- CUR,  PDT,    The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro
- in-vitro, Bladder, RT112 - in-vitro, Bladder, UMUC3
Apoptosis↑, TumCG↓, TumCP↓,
473- CUR,    Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade
- in-vitro, Oral, HSC4 - in-vitro, Oral, Ca9-22
Vim↓, p‑cMET↓, p‑ERK↓, pro‑MMP9↓, E-cadherin↑,
484- CUR,  PDT,    Low concentrations of curcumin induce growth arrest and apoptosis in skin keratinocytes only in combination with UVA or visible light
- in-vitro, Melanoma, NA
Cyt‑c↑, Casp9↑, Casp8↑, NF-kB↓, EGFR↓,
485- CUR,  PDT,    Red Light Combined with Blue Light Irradiation Regulates Proliferation and Apoptosis in Skin Keratinocytes in Combination with Low Concentrations of Curcumin
- in-vitro, Melanoma, NA
NF-kB↓, Casp8↑, Casp9↑, p‑Akt↓, p‑ERK↓,
872- CUR,  RES,    New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects
- in-vitro, BC, TUBO - in-vitro, BC, SALTO
TumCP↓, tumCV↓, p62↓, p62↑, TumAuto↑, TumAuto↓, ROS↑, ROS↓, CHOP↑,
933- CUR,  EP,    Effective electrochemotherapy with curcumin in MDA-MB-231-human, triple negative breast cancer cells: A global proteomics study
- in-vitro, BC, NA
Apoptosis↑, ALDOA↓, ENO2↓, LDHA↓, LDHB↓, PFKP↓, PGK1↓, PGM1↓, PGAM1↓, OXPHOS↑, TCA↑,
990- CUR,    Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT-29
HK2↓, Glycolysis↓, Apoptosis↑,
1006- CUR,    The effect of Curcuma longa extract and its active component (curcumin) on gene expression profiles of lipid metabolism pathway in liver cancer cell line (HepG2)
- in-vitro, Liver, HepG2
TumCP↓, PGC1A↑, CPT1A↑, ACOX1↑, SCD1↓, SREBF2↓, DGAT1↓,
1034- CUR,  immuno,    Enhanced anti‐tumor effects of the PD‐1 blockade combined with a highly absorptive form of curcumin targeting STAT3
- in-vivo, NA, NA
DCells↑, T-Cell↑,
1108- CUR,    Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition
- Review, NA, NA
EMT↓,
1383- CUR,  BBR,  RES,    Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases
- Review, NA, NA
GSK‐3β↝, ROS↑,
142- CUR,    Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts
- in-vivo, Pca, LNCaP
AR↓, PSA↓,
131- CUR,    Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer
- vitro+vivo, Pca, LNCaP - vitro+vivo, Pca, 22Rv1
AKR1C2↓, CYP11A1↓, HSD3B↓, DHT↓, testos↓, StAR↓, SRD5A1↑, AR↓, tumCV↓, TumCG↓, Apoptosis↑,
132- CUR,    Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells
- in-vitro, Pca, PC3
TumCCA↑, ROS↑, TumAuto↑, UPR↑, ER Stress↑, Casp3↑, Casp9↑, Casp12↑, PARP↑, other↝, GRP78/BiP↑, PDI↑, eIF2α↑, other↝,
133- CUR,    Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
miR-143↑, PDK1↓, FOXD3↑, TumCP↓, TumCMig↓, *Inflam↓, *antiOx↑, *chemoPv↑, RadioS↑, ChemoSen↑,
134- CUR,  RES,  MEL,  SIL,    Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
Apoptosis↑, ROS↑, Trx1↓, TumCG↓, eff↓, TXNIP↑,
135- CUR,    Curcumin induces apoptosis and protective autophagy in castration-resistant prostate cancer cells through iron chelation
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TfR1/CD71↑, IRP1↑, IronCh↑, Casp↑, eff↑,
136- CUR,  docx,    Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, ChemoSen↑,
137- CUR,    Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling
- in-vitro, Pca, DU145
NOTCH1↓, cycD1/CCND1↓, CDK2↓, P21↑, p27↑, P53↑, Bcl-2↓, Casp3↑, Casp9↑, TumCCA↑, TumCP↓, Apoptosis↑,
140- CUR,    Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling
- in-vitro, Pca, PC3
CAFs/TAFs↓, EMT↓, ROS↓, CXCR4↓, IL6↓, MAOA↓, mTOR↓, HIF-1↓,
141- CUR,    Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer
- in-vivo, Pca, PC3
BAX↑, Bcl-2↓, TumCG↓, TumVol↓, TumW↓, Apoptosis↑, AR↓, Ca+2↑, MPT↑,
130- CUR,    Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
BAD↝, BAX↝, eff↑,
143- CUR,    Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ER Stress↑, CHOP↑, GRP78/BiP↑, ROS↑, LC3II↑, eff↓, tumCV↓,
144- CUR,  Bical,    Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C
- in-vitro, Pca, PC3 - in-vitro, PC, DU145 - in-vitro, PC, LNCaP
p‑ERK↑, p‑JNK↓, MUC1↓, p65↓, AR↓, TumCG↓, MEK↑, SAPK↑,

Showing Research Papers: 151 to 200 of 293
Prev Page 4 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 293

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   mt-GSH↓, 1,   GSH/GSSG↓, 1,   IRP1↑, 1,   OXPHOS↑, 1,   ROS↓, 3,   ROS↑, 11,   Trx↓, 1,   Trx1↓, 2,   Trx2↓, 1,   TrxR↓, 5,   TrxR1↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,   TfR1/CD71↑, 1,  

Mitochondria & Bioenergetics ⓘ

CDC25↓, 1,   MEK↑, 1,   MMP↓, 2,   MPT↑, 1,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACOX1↑, 1,   ALDOA↓, 1,   CPT1A↑, 1,   DGAT1↓, 1,   ENO2↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   LDHA↓, 1,   LDHB↓, 1,   PDK1↓, 1,   PFKP↓, 1,   PGAM1↓, 1,   PGC1A↑, 1,   PGK1↓, 1,   PGM1↓, 1,   PI3K/Akt↓, 1,   SCD1↓, 1,   SREBF2↓, 1,   TCA↑, 1,  

Cell Death ⓘ

p‑Akt↓, 3,   Apoptosis↑, 15,   BAD↝, 1,   BAX↑, 3,   BAX↝, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Bcl-xL↓, 1,   BID↑, 1,   Casp↑, 1,   Casp12↑, 1,   Casp3↑, 3,   cl‑Casp3↑, 3,   Casp8↑, 2,   Casp9↑, 4,   Cyt‑c↑, 3,   p‑JNK↓, 1,   Mcl-1↓, 1,   p27↑, 1,   TumCD↑, 1,   β-TRCP↑, 1,  

Kinase & Signal Transduction ⓘ

FOXD3↑, 1,   HER2/EBBR2↓, 1,   RTK-RAS↓, 1,  

Transcription & Epigenetics ⓘ

HATs↓, 1,   miR-143↑, 1,   other↝, 2,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 2,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↑, 1,   p62↓, 1,   p62↑, 2,   TumAuto↓, 1,   TumAuto↑, 3,  

DNA Damage & Repair ⓘ

DNA-PK↑, 1,   DNAdam↑, 1,   mt-DNAdam↑, 1,   DNMTs↓, 1,   P53↑, 3,   p73↑, 1,   PARP↑, 2,   cl‑PARP↑, 3,   SAPK↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   P21↑, 2,   TumCCA↑, 7,  

Proliferation, Differentiation & Cell State ⓘ

p‑cMET↓, 1,   EMT↓, 3,   ERK↑, 1,   p‑ERK↓, 2,   p‑ERK↑, 1,   GSK‐3β↝, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC3↓, 1,   HDAC8↓, 1,   mTOR↓, 1,   p‑mTOR↓, 1,   NOTCH1↓, 2,   p300↓, 1,   Pirin↓, 1,   PTEN↑, 1,   STAT3↓, 1,   TumCG↓, 5,  

Migration ⓘ

AKR1C2↓, 1,   Ca+2↑, 1,   CAFs/TAFs↓, 1,   E-cadherin↑, 2,   miR-340↑, 1,   pro‑MMP9↓, 1,   MUC1↓, 1,   N-cadherin↓, 1,   NEDD9↓, 2,   PIR↓, 1,   Slug↓, 1,   TumCI↓, 1,   TumCMig↓, 4,   TumCP↓, 10,   TXNIP↑, 1,   Vim↓, 2,   Zeb1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 2,   HIF-1↓, 1,   PDI↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CXCR4↓, 1,   DCells↑, 1,   IL6↓, 2,   NF-kB↓, 6,   p65↓, 1,   PSA↓, 1,   T-Cell↑, 1,  

Synaptic & Neurotransmission ⓘ

MAOA↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 4,   CYP11A1↓, 1,   DHT↓, 1,   HSD3B↓, 1,   SRD5A1↑, 1,   StAR↓, 1,   testos↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 6,   Dose?, 1,   Dose↑, 2,   Dose↝, 1,   Dose∅, 1,   eff↓, 2,   eff↑, 8,   RadioS↑, 6,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 4,   EGFR↓, 2,   HER2/EBBR2↓, 1,   IL6↓, 2,   PSA↓, 1,  

Functional Outcomes ⓘ

chemoP↑, 2,   ChemoSideEff↓, 1,   OS↓, 1,   QoL↑, 1,   radioP↑, 1,   TumVol↓, 2,   TumW↓, 1,  
Total Targets: 169

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GPx↑, 1,   GSH↑, 2,   HO-1↑, 1,   NRF2↑, 2,   ROS↓, 3,  

Core Metabolism/Glycolysis ⓘ

NADPH↑, 1,  

Cell Death ⓘ

Akt↓, 1,   iNOS↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p300↓, 1,   STAT3↓, 1,  

Migration ⓘ

5LO↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   MMPs↑, 1,   TIMP1↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   IL1↓, 1,   IL12↓, 1,   IL2↑, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 3,   MCP1↓, 1,   NF-kB↓, 2,   PGE2↓, 2,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

MAOA↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioEnh↑, 1,   Dose∅, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

chemoPv↑, 1,   OS↑, 1,  
Total Targets: 36

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:65  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page